In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed:1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: …
A risk classification system using C-reactive protein (CRP) levels and hypercalcemia is “useful for predicting the outcomes” of patients receiving enfortumab vedotin.
David Morris, MD, FACS, of Urology Associates of Nashville, discusses the emerging role of copper-based PSMA imaging agents, specifically Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA.
The phase 3 AMPLIFY study provides evidence that fixed-duration acalabrutinib plus venetoclax may be a valid treatment option for fit patients with treatment-naive CLL.
AbstractBackgroundDonor-recipient heart size matching is crucial in heart transplantation; however, the often-used predicted heart mass (PHM) ratio may be inaccurate in the setting of obesity.Objec…
The retrospective analysis reaffirmed evidence from CCTG BR.34 that showed bone metastasis was associated with worse outcomes in ICI-treated NSCLC, with or without chemotherapy.
A study evaluated kidney outcomes of angiotensin receptor-neprilysin inhibitor therapy versus ACEI/ARB for thrombotic microangiopathy related to malignant hypertension.
AbstractBackgroundConsidering the high prevalence of mitral regurgitation (MR) and the highly subjective, variable MR severity reporting, an automated tool that could screen patients for clinically…
FDA Approves New Drug to Treat a Serious Immune Condition that Can Affect Children with Blood Cancer > Page Components
AbstractPrimary cardiac tumors are a rare disease, with 20% of the cases being malignant. Among them, angiosarcoma is characterized by a short clinical course and…
The standard strategy for TLS mitigation is dose escalation and TLS monitoring during dose ramp-up, and there is an ongoing debate on whether the standard…
